Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome
Conditions
Interventions
ZYN002 - Cannabidiol Transdermal Gel
Placebo Transdermal Gel
Locations
21
United States
Southwest Autism Research and Resource Center
Phoenix, Arizona, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
UC Davis Health System, MIND Institute
Sacramento, California, United States
Children's Hospital of Colorado
Denver, Colorado, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Start Date
June 12, 2018
Primary Completion Date
June 14, 2020
Completion Date
June 14, 2020
Last Updated
July 6, 2022
NCT06560242
NCT06139172
NCT05418049
NCT07439510
NCT06957054
NCT06261502
Lead Sponsor
Zynerba Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions